Interactive effect of MDM2 and TP53 genotypes
| Effect . | University of Chicago . | United Kingdom . | Combined analysis . | ||||
|---|---|---|---|---|---|---|---|
| No. patients (%) . | No. controls (%) . | OR(95% CI) . | No. patients(%) . | No. controls(%) . | OR(95% CI) . | Site-adjusted OR (95% CI) . | |
| On development of t-AML (MDM2 TP53 genotype*) | |||||||
| MDM2 TT TP53 Pro/Pro, Arg/Pro | 9 (12) | 406 (19) | 1.0 (Ref) | 11 (12) | 134 (19) | 1.0 (Ref) | 1.0 (Ref) |
| MDM2 TT TP53 Arg/Arg | 22 (28) | 488 (23) | 2.03 (0.93-4.47) | 24 (27) | 186 (26) | 1.57 (0.74-3.32) | 1.78 (1.03-3.06) |
| MDM2 TG, GG TP53 Pro/Pro, Arg/Pro | 27 (35) | 519 (25) | 2.35 (1.09-5.05) | 25 (28) | 172 (24) | 1.77 (0.84-3.73) | 2.04 (1.20-3.48) |
| MDM2 TG, GG TP53 Arg/Arg | 20 (26) | 705 (33) | 1.28 (0.58-2.84) | 29 (33) | 211 (30) | 1.67 (0.81-3.46) | 1.48 (0.86-2.52) |
| P for interaction† | .009 | .29 | .009 | ||||
| On development of t-AML with any prior chemotherapy (MDM2 TP53 genotype*) | |||||||
| MDM2 TT TP53 Pro/Pro, Arg/Pro | 8 (12) | 406 (19) | 1.0 (Ref) | 5 (10) | 134 (19) | 1.0 (Ref) | 1.0 (Ref) |
| MDM2 TT TP53 Arg/Arg | 19 (28) | 488 (23) | 1.98 (0.86-4.56) | 15 (30) | 186 (26) | 2.16 (0.77-6.09) | 2.04 (1.07-3.92) |
| MDM2 TG, GG TP53 Pro/Pro, Arg/Pro | 22 (32) | 519 (25) | 2.15 (0.95-4.88) | 12 (24) | 172 (24) | 1.87 (0.64-5.44) | 2.05 (1.07-3.92) |
| MDM2 TG, GG TP53 Arg/Arg | 19 (28) | 705 (33) | 1.37 (0.59-3.15) | 18 (36) | 211 (30) | 2.29 (0.83-6.30) | 1.70 (0.89-3.23) |
| P for interaction† | .033 | .38 | .029 | ||||
| On development of t-AML with abnormalities of chromosome 5 and/or 7 (MDM2 TP53 genotype*) | |||||||
| MDM2 TT TP53 Pro/Pro, Arg/Pro | 6 (12) | 406 (19) | 1.0 (Ref) | 3 (13) | 134 (19) | 1.0 (Ref) | 1.0 (Ref) |
| MDM2 TT TP53 Arg/Arg | 13 (26) | 488 (23) | 1.80 (0.68-4.78) | 6 (27) | 186 (26) | 1.44 (0.35-5.86) | 1.68 (0.75-3.74) |
| MDM2 TG, GG TP53 Pro/Pro, Arg/Pro | 16 (32) | 519 (25) | 2.09 (0.81-5.38) | 11 (50) | 172 (24) | 2.86 (0.78-10.44) | 2.34 (1.09-5.02) |
| MDM2 TG, GG TP53 Arg/Arg | 19 (30) | 705 (33) | 1.44 (0.55-3.74) | 2 (9) | 211 (30) | 0.42 (0.07-2.57) | 1.12 (0.50-2.53) |
| P for interaction† | .12 | .03 | .015 | ||||
| Effect . | University of Chicago . | United Kingdom . | Combined analysis . | ||||
|---|---|---|---|---|---|---|---|
| No. patients (%) . | No. controls (%) . | OR(95% CI) . | No. patients(%) . | No. controls(%) . | OR(95% CI) . | Site-adjusted OR (95% CI) . | |
| On development of t-AML (MDM2 TP53 genotype*) | |||||||
| MDM2 TT TP53 Pro/Pro, Arg/Pro | 9 (12) | 406 (19) | 1.0 (Ref) | 11 (12) | 134 (19) | 1.0 (Ref) | 1.0 (Ref) |
| MDM2 TT TP53 Arg/Arg | 22 (28) | 488 (23) | 2.03 (0.93-4.47) | 24 (27) | 186 (26) | 1.57 (0.74-3.32) | 1.78 (1.03-3.06) |
| MDM2 TG, GG TP53 Pro/Pro, Arg/Pro | 27 (35) | 519 (25) | 2.35 (1.09-5.05) | 25 (28) | 172 (24) | 1.77 (0.84-3.73) | 2.04 (1.20-3.48) |
| MDM2 TG, GG TP53 Arg/Arg | 20 (26) | 705 (33) | 1.28 (0.58-2.84) | 29 (33) | 211 (30) | 1.67 (0.81-3.46) | 1.48 (0.86-2.52) |
| P for interaction† | .009 | .29 | .009 | ||||
| On development of t-AML with any prior chemotherapy (MDM2 TP53 genotype*) | |||||||
| MDM2 TT TP53 Pro/Pro, Arg/Pro | 8 (12) | 406 (19) | 1.0 (Ref) | 5 (10) | 134 (19) | 1.0 (Ref) | 1.0 (Ref) |
| MDM2 TT TP53 Arg/Arg | 19 (28) | 488 (23) | 1.98 (0.86-4.56) | 15 (30) | 186 (26) | 2.16 (0.77-6.09) | 2.04 (1.07-3.92) |
| MDM2 TG, GG TP53 Pro/Pro, Arg/Pro | 22 (32) | 519 (25) | 2.15 (0.95-4.88) | 12 (24) | 172 (24) | 1.87 (0.64-5.44) | 2.05 (1.07-3.92) |
| MDM2 TG, GG TP53 Arg/Arg | 19 (28) | 705 (33) | 1.37 (0.59-3.15) | 18 (36) | 211 (30) | 2.29 (0.83-6.30) | 1.70 (0.89-3.23) |
| P for interaction† | .033 | .38 | .029 | ||||
| On development of t-AML with abnormalities of chromosome 5 and/or 7 (MDM2 TP53 genotype*) | |||||||
| MDM2 TT TP53 Pro/Pro, Arg/Pro | 6 (12) | 406 (19) | 1.0 (Ref) | 3 (13) | 134 (19) | 1.0 (Ref) | 1.0 (Ref) |
| MDM2 TT TP53 Arg/Arg | 13 (26) | 488 (23) | 1.80 (0.68-4.78) | 6 (27) | 186 (26) | 1.44 (0.35-5.86) | 1.68 (0.75-3.74) |
| MDM2 TG, GG TP53 Pro/Pro, Arg/Pro | 16 (32) | 519 (25) | 2.09 (0.81-5.38) | 11 (50) | 172 (24) | 2.86 (0.78-10.44) | 2.34 (1.09-5.02) |
| MDM2 TG, GG TP53 Arg/Arg | 19 (30) | 705 (33) | 1.44 (0.55-3.74) | 2 (9) | 211 (30) | 0.42 (0.07-2.57) | 1.12 (0.50-2.53) |
| P for interaction† | .12 | .03 | .015 | ||||